



## Financial Tear Sheet

### Corporate Profile

Rigel's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent **ITP**. The investigation of fostamatinib also includes Phase 2 clinical trials for **autoimmune hemolytic anemia (AIHA)** and **IgA nephropathy (IgAN)**. In addition, Rigel has product candidates in development with partners **BerGenBio AS**, **Daichi Sankyo**, and **Aclaris Therapeutics**.

### Recent News

Date	Title
01/04/18	Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
12/15/17	Rigel Announces Departure of Chief Financial Officer

### Stock Performance

RIGL (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$3.87
Change (%)	-0.08 (2.03%)
Volume	666,693
Data as of 02/16/18 4:00 p.m. ET <a href="#">Refresh quote</a>	



Data provided by Nasdaq. Minimum 15 minutes delayed.

### SEC Filings

Filing Date	Form
02/14/18	SC 13G/A
02/13/18	SC 13G/A

### Primary IR Contact

Ryan Maynard  
 CFO  
 Phone: (650) 624-1284  
 E-mail: [invrel@rigel.com](mailto:invrel@rigel.com)